Obu Biology (300357.SZ): Application for clinical trial of the drug “Human Umbilical Cord Mesenchymal Stem Cell Type II Injection” was accepted

Zhitong Finance App News, Wuwu Biotech (300357.SZ) issued an announcement. In June 2026, the company disclosed the “Notice Concerning Withdrawal of Drug Clinical Trial Applications”. Zhejiang Wuwu Stem Cell Technology Co., Ltd. (hereinafter referred to as “Zhejiang Stem Cell”), an indirect holding subsidiary of the company, submitted another application for drug clinical trials after completing relevant pharmaceutical research. Recently, Zhejiang stem cells obtained the “Notice of Acceptance” issued by the State Drug Administration, and the “human umbilical cord mesenchymal stem cell type II injection” drug clinical trial application submitted by Zhejiang stem cells has been officially accepted.

As of the disclosure date of this announcement, no mesenchymal stem cell drugs to treat sepsis and septic shock have been approved for marketing at home or abroad. Sepsis is a clinical syndrome with a high case fatality rate due to host dysfunction caused by infection, leading to life-threatening organ dysfunction. Septic shock is sepsis combined with severe circulatory, cellular, and metabolic disorders, and the risk of death is higher than sepsis alone. The pathophysiological mechanisms of sepsis and septic shock are complex, often leading to multiple organ dysfunction and poor prognosis. Surviving patients may have cognitive impairment and organ dysfunction, and impaired quality of life. Currently, treatment strategies for sepsis and septic shock are mainly limited to supportive treatment and the application of broad-spectrum antimicrobials. Despite continuous advances in liquid resuscitation, vasoactive drugs, and organ function support technology, the case fatality rate and long-term complication rate of patients with sepsis and septic shock remain high, and breakthrough treatment strategies are still needed.